3
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Thoracic Malignancies
- Tumour Sub-type
- Non-small-cell Lung Cancer
- Tumour Sub-Group
- ROS1+
- Tumour stage
- Advanced
- Control Arm
- Single arm study
- Treatment Setting
- Cohort study 50 patients (86% had received at least one previous line of standard therapy)
Primary Outcome(s)
- Primary Outcome(s)
- ORR and mPFS (Phase I)
- Form(s)
- Form 3
Outcome Data
- ORR
- 72% achieved in ORR (95% CI 58-84), mPFS 19.2 months (95% CI 14.4 - not reached)
Final Score (after adjustments)
- Preliminary non-curative score
- 3
- Final non-curative Score
- 3
- Release date
- 16.05.2019
DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; HR, hazard ratio; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate